



The interplay between HIV and COVID-19: summary of the data and responses to date

*Lillian B. Brown**, *Matthew A. Spinelli**, and *Monica Gandhi*

Purpose of review

We examine the interplay between the HIV and COVID-19 epidemics, including the impact of HIV on COVID-19 susceptibility and severe disease, the effect of the COVID-19 epidemic on HIV prevention and treatment, and the influence of the HIV epidemic on responses to COVID-19.

Recent findings

Evidence to date does not suggest that people living with HIV (PLWH) have a markedly higher susceptibility to SARS-CoV-2 infection, with disparities in the social determinants of health and comorbidities likely having a greater influence. The majority of literature has not supported a higher risk for severe disease among PLWH in Europe and the United States, although a large, population-based study in South Africa reported a higher rate of death due to COVID-19. Higher rates of comorbidities associated with COVID-19 disease severity among PLWH is an urgent concern. COVID-19 is leading to decreased access to HIV prevention services and HIV testing, and worsening HIV treatment access and virologic suppression, which could lead to worsening HIV epidemic control.

Conclusion

COVID-19 is threatening gains against the HIV epidemic, including the U.S. Ending the HIV Epidemic goals. The ongoing collision of these two global pandemics will continue to need both study and interventions to mitigate the effects of COVID-19 on HIV efforts worldwide.

Keywords

clinical outcomes, COVID-19, HIV, incidence, severe disease

INTRODUCTION

An unprecedented public health emergency is unfolding worldwide with the COVID-19 pandemic [1]. In response to multiple outbreaks from January to February 2020, a massive public health response was mounted globally, with cities, states and countries imposing school closures, prohibition of public gatherings, 'shelter in place' ordinances and closures of establishments that provide nonessential services. Medical care was also closed for 'nonessential' functions. The COVID-19 epidemic led HIV clinics to cancel nonurgent visits; convert in-person visits to remote telephone visits for needed care; divert HIV and Infectious Diseases providers to inpatient, public health, occupational health or logistical duties; and decrease routine laboratory testing and social services for people living with HIV (PLWH). In the space of weeks, the HIV care system globally changed from efforts to link and retain patients into care to instead limit in-person clinical visits for patients with chronic diseases. Although care is now opening up for patients with chronic illness

worldwide, the impact of this paradigm shift for HIV testing, prevention and care worldwide will set back HIV epidemic control efforts for some time.

Beyond the effects of the COVID-19 pandemic on HIV outcomes, it is critical to examine whether HIV has an impact on COVID-19 susceptibility or severity of outcomes [2,3]. Some of the risk factors for severe COVID-19 [4–9] (older age [10], cardiovascular disease (CVD) [11], pulmonary disease [12,13]) are more prevalent in PLWH than those without HIV, although HIV itself may not predispose to markedly more severe COVID-19 outcomes.

Division of HIV, ID, and Global Medicine, University of California, San Francisco, California, USA

Correspondence to Monica Gandhi, 995 Potrero Avenue, Ward 84, San Francisco, CA 94110, USA. Tel: +1 415 476 4082 x138; e-mail: Monica.Gandhi@UCSF.edu

*Lillian B. Brown and Matthew A. Spinelli both contributed equally to this study.

Curr Opin HIV AIDS 2021, 16:63–73

DOI:10.1097/COH.0000000000000659

KEY POINTS

- Evidence to date does not suggest that people living with HIV have a markedly higher susceptibility to SARS-CoV-2 infection.
- The majority of literature has not supported a higher risk for severe disease among people living with HIV in Europe and the United States, although a large, population-based study in South Africa reported a higher rate of death due to COVID-19.
- COVID-19 is leading to decreased access to HIV prevention services and HIV testing, and worsening HIV treatment access and virologic suppression, which could lead to worsening HIV epidemic control.
- The experience of the HIV epidemic has influenced scientific, public health and regulatory responses to COVID-19.

Relatively large studies have now been published examining the impact of HIV on COVID-19 risk and outcomes, which now require synthesis.

No prior global pandemic of the scale of COVID-19 has overlapped temporally with the HIV pandemic, so periodic review of the interplay between the two infections is important for the field. In this review, we explore available evidence on the susceptibility of PLWH to SARS-CoV-2 infection and severe

COVID-19 disease, the impact of COVID-19 and its public health response on control efforts for HIV, and similarities in responses to the two pandemics.

IMPACT OF HIV ON COVID-19

Impact of HIV on susceptibility to SARS-CoV-2 infection

Early data on the impact of HIV on susceptibility to COVID-19 infection were mostly limited to PLWH on antiretroviral therapy (ART) in the early stages of the COVID-19 epidemic when testing was primarily limited to those with symptoms (Fig. 1). Two studies from Spain initially suggested a lower incidence of COVID-19 infection among PLWH than the general population. In a single-centre prospective cohort in Barcelona that included 5683 PLWH (99%) on ART, 53 (0.9%, 95% confidence interval 0.7–1.3) developed confirmed or suspected COVID-19 infection during the study period and the standardized incident rate ratio of confirmed infection was 38% (95% confidence interval 27–52) compared with the general population [14¹⁴]. A prospective cohort study among HIV clinics in 60 hospitals that serve 77 590 PLWH in the Madrid region observed 236 diagnosed COVID-19 infections among PLWH. This study also estimated a lower age and sex-standardized risk of confirmed COVID-19 infection among PLWH on




FIGURE 1. Evidence to date of COVID-19 susceptibility and propensity to severe disease among people living with HIV compared to the general population.

ART than the general population (30 per 10 000 among PLWH vs. 41.7 per 10 000 among the general population) [15^{***}]. However, the estimated risk of infection was similar for PLWH when healthcare workers were excluded from the sample (30 per 10 000 among PLWH vs. 33.0 per 10 000 among the general population) [15^{***}].

In contrast, a study in France which included 77 COVID-19 diagnoses among PLWH estimated similar attack rates of COVID-19 among PLWH and the general population; in this study, HIV was not associated with COVID-19 infection in multivariable analysis [16]. A small population cohort in Wuhan, China, observed similar standardized incidence rates of COVID-19 among 6001 PLWH (0.38%, 95% confidence interval 0.24–0.53) to the general population (0.45%, 95% confidence interval 0.45–0.46) [17^{*}]. In both studies, 99% of PLWH were on ART during the study period. The Veterans Aging Cohort Study (VACS), which included 253 PLWH co-infected with COVID-19, found higher testing rates among PLWH than those without HIV, but similar test positivity rates, with 9.7% of PLWH vs. 10.1% of HIV-uninfected veterans diagnosed with COVID-19 from February to April 2020 [18^{***}]. Finally, in a population-based study in San Francisco, PLWH were more likely to test positive for COVID-19 during the first 6 months of community spread, with a 4.5% positivity rate among PLWH (193/4252) compared with 3.5% (9626/272 555) among people without HIV [19^{***}]. Among the PLWH coinfecting with COVID-19 in this study, only 44% were virally suppressed at their most recent laboratory test.

The incidence of COVID-19 among PLWH may be more influenced by the differential impact of comorbidities and social determinants of health among PLWH that mediate risk of exposure to COVID-19 infection rather than HIV itself. Higher rates of chronic lung disease [12] and behaviours that impact lung function, such as cigarette smoking [20], inhalational drug use [21] and hazardous alcohol use [22,23] among PLWH in the U.S. may also increase the risk of SARS-CoV-2 infection. PLWH experience higher rates of homelessness and unstable or crowded housing than the general population [24,25], and increased time in homeless shelters and congregate living settings may decrease their ability to socially distance or effectively quarantine [26^{***},27]. Among the 193 PLWH who tested positive for COVID-19 in San Francisco over the first 6 months of the pandemic, only 100 (55%) were housed. Conversely, PLWH who experienced the early days of the HIV pandemic may be more likely to shelter in place.

In conclusion, the studies to date do not support that PLWH are generally more susceptible to

COVID-19 by virtue of HIV infection itself, although PLWH may be more likely to be tested for SARS-CoV-2, experience other risk factors (e.g. congregate living situations) that make social distancing difficult and increase the risk of exposure to the virus, and/or have increased rates of smoking or chronic lung disease which may increase the risk of infection once exposed.

Impact of HIV on severity of outcomes with COVID-19 disease

In general, PLWH seem to experience similar clinical outcomes with COVID-19 infection than those without HIV in series from the U.S. and Europe (Figure) [14^{**},28–33,17^{*},34^{**},35]. The risk of severe COVID-19 outcomes was similar by HIV status in the VACS cohort, one of the largest cohorts of COVID-19/HIV co-infection ($n = 253$) reported from the U.S. to date [18^{***}]. A multicentre registry-based cohort of 286 PLWH from 36 institutions in 21 U.S. states and three international sites (two in Spain and one in Singapore) found clinical outcomes of similar severity to those reported among HIV-negative individuals in the U.S. [36]. In this cohort, a CD4⁺ cell count less than 200 cells/ μ l was associated with decreased overall survival, while viral non-suppression was not [36]. PLWH who tested positive for COVID-19 in San Francisco ($n = 193$) also did not experience an increased rate of severe illness relative to those without HIV [19^{***}], despite high rates of virologic non-suppression (56%) in this sample. In a matched case-control study comparing 21 PLWH on ART to 42 HIV-uninfected patients hospitalized with COVID-19 in New York, PLWH had higher C-reactive protein (CRP) values and were more likely to have abnormal chest X-rays at admission [37]. Compared with the control group, a higher proportion of PLWH required ICU admission (29 vs. 18%) and mechanical ventilation (24 vs. 12%); however, these differences were not statistically significant, and there were no differences in mortality (29 vs. 24%, $P = 0.7$) [37]. A small case series of 14 PLWH infected with COVID-19 in Wuhan observed a higher proportion of severe cases and higher mortality than the general population; however, the median age and number of comorbidities was also higher among PLWH in that study than the general population of Wuhan [38].

The largest study to address risk of death from COVID-19 among PLWH is a prospective cohort study in South Africa, which includes 3 460 932 patients served by the public sector healthcare system in Western Cape Province, 3978 (16%) of whom are PLWH. In this province, 22 308 were diagnosed with COVID-19, from 1 March to 9 June 2020, of

whom 625 died [39^{***}]. This cohort observed an increased hazard rate of COVID-19 death adjusted for age and sex among PLWH compared with the general population, with a standardized mortality ratio of 2.39 (95% confidence interval 1.96–2.86) [39^{***}]. The median age of death from COVID-19 was also younger among PLWH than the general population in the Western Cape cohort and a greater proportion of COVID-19 deaths were in patients aged less than 50 years in those with vs. without HIV (39 vs. 13%). Several factors could explain the differences in the findings of the South African cohort compared with the European and American cohorts. For instance, only 55% of the South African cohort were on ART and virologically suppressed, and comorbidity burden also differed when compared with European and U.S. cohort, with high numbers of PLWH having uncontrolled diabetes and active tuberculosis.

In addition to the potential impact of HIV on COVID-19 susceptibility, PLWH globally may be more at risk for more severe disease from COVID-19 due to a disproportionate burden of known risk factors associated with severe COVID-19 disease [40]. Nearly half of the PLWH in the U.S. are older than 50 years [10]. PLWH have a higher rate of cardiovascular disease [11], including hypertension [41] and pulmonary disease [12,13] than the general population, as well as high rates of smoking [20,42,43]. Published case series to date describe a high burden of comorbidities among PLWH who are coinfecting with COVID-19 across different settings [28,33,34^{***},38,44,45^{*}]. In the predominantly U.S. multicentre cohort of 286 PLWH, having three or more comorbidities was associated with both hospitalization and severe outcomes in adjusted analysis [36].

The conclusion of all of these studies is that PLWH did not seem to be at an increased risk of severe outcomes with COVID-19 in studies to date within the U.S. and Europe [46], while HIV was associated with a higher mortality rate due to COVID-19 in a large cohort in South Africa. The larger population-based study in South Africa may better estimate the impact of HIV on severe COVID-19 disease, or differing comorbidity burdens and viral suppression between these settings could explain these differences. Comorbidities such as diabetes and cardiovascular disease that are prevalent among PLWH may compound potential risks of HIV itself, and controlling modifiable risk factors previously associated with COVID-19 disease severity among PLWH is therefore important for multiple reasons. Finally, longitudinal data from diverse settings across the world and across the spectrum of COVID-19 disease severity will eventually provide a

more complete picture of the impact of HIV on COVID-19 disease over time.

The possible effect of antiretroviral therapy on COVID-19 disease susceptibility or outcomes

Speculation that PLWH may have reduced susceptibility to SARS-CoV-2 or severe COVID-19 outcomes has arisen from the fact that different ART components have activity against enzymes involved in SARS-CoV-2 replication *in vitro*. Lopinavir has *in vitro* activity against proteases from both SARS-CoV [47] and MERS-CoV [48] as well as some benefit in animal models of MERS-CoV [49]. Atazanavir also docks in the active site of SARS-CoV-2 major protease, blocks its activity *in vitro* and inhibits SARS-CoV-2 replication in a cell line [50]. Early case series of HIV/COVID-19-infected patients described multiple instances of changing ART regimens to include protease inhibitors [3,30]. However, two clinical trials have now examined the effect of lopinavir/ritonavir on the clinical course of COVID-19, including the pragmatic RECOVERY trial, and found no benefit in using this protease inhibitor in either shortening the disease course or decreasing mortality from COVID-19 [51^{*},52^{***}]. Moreover, pharmacokinetic studies suggest that lopinavir/ritonavir at currently-used doses will not achieve sufficient concentrations for efficacy against SARS-CoV-2 [53].

Tenofovir, a nucleotide analogue that resembles remdesivir, has been shown to bind the SARS-CoV-2 polymerase *in vitro* [54]. In an analysis among PLWH and PrEP users from a single centre in France, tenofovir use (either in ART or PrEP) was not associated with the risk of COVID-19 infection or clinical course [16]. In contrast, tenofovir disoproxil fumarate (TDF)-based ART, but not tenofovir alafenamide (TAF), among a cohort of 77 590 PLWH across 60 clinics in Spain was associated with lower rates of both COVID-19 diagnosis and hospitalization [15^{***}]. This finding may actually reflect channelling bias, as patients who are healthier without comorbidities (such as renal insufficiency) may be more likely to be placed on a TDF-containing vs. TAF-containing regimens. In the Western Cape Cohort, TDF was also associated with fewer COVID-19 related deaths, although PLWH not on TDF would be likely to be receiving second-line ART or have renal dysfunction in this setting [39^{***}]. A randomized controlled trial to ascertain whether TDF/emtricitabine protects healthcare workers from contracting SARS-CoV-2 in Spain is ongoing. Guidelines from the Department of Health and Human Services and the National Institutes of Health continue to recommend against changing ART for the purpose of preventing or treating COVID-19 [55,56].

IMPACT OF COVID-19 ON HIV

Impact of COVID-19 on HIV epidemic control and the health of people living with HIV

The 1918 influenza pandemic influenced health outcomes for the public for decades afterwards due to disruptions in the medical system, interruptions in care for chronic illness and the stress and turbulence of the time [57–60]. The recent Ebola outbreak in West Africa disrupted care for a number of chronic illnesses, including HIV via decreases in testing [61] and ART access [10,61–63]. Similarly, the impact of the shutdown of medical and social services for PLWH is likely to hamper HIV epidemic control. Indeed, the current crisis has the potential to significantly set back the progress made so far towards the UNAIDS 90–90–90 goals and the United States Ending the HIV Epidemic (EtHE) initiative [64,65].

Impact on HIV susceptibility, testing, prevention and treatment access

The COVID-19 epidemic has imperilled the health and well being of PLWH, while disrupting the four key pillars of HIV epidemic control highlighted by the UNAIDS 90–90–90 and the United States Ending

the HIV Epidemic initiatives: HIV Prevention, Diagnosis, Treatment and Outbreak Control (Fig. 2) [64]. Beyond these four pillars, the COVID-19 pandemic is likely to have an impact on HIV susceptibility and risk, which may have decreased in the few months following the pandemic, but could increase due to adverse socioeconomic conditions resulting from the COVID-19 epidemic and widespread lockdowns [66]. For instance, in a survey of 20 238 LGBTQ individuals from 138 countries in April–May, 2020 presented at the *AIDS 2020* meeting in July, 57.8% reported having either lost their job, at high risk of losing their job, or being unsure about employment in the near future [67^{***}]. Moreover, 44% had experienced reductions in salary, 23% reported new food insecurity and 1% had exchanged sex for money or resources.

Disruption of healthcare systems due to COVID-19 [68], shelter-in-place orders [61] and fear of infection at care sites [69] are also threatening access to HIV testing, prevention and treatment services. In the same study of more than 20 000 LGBTQ individuals across the world, over 50% reported uncertain or no access to PrEP during the pandemic [67^{***}]. A study of 3520 PrEP users from a large PrEP provider in Boston reported a 72% decrease in PrEP




FIGURE 2. Impact of COVID-19 on HIV susceptibility, testing, prevention and treatment.

initiations, an increase in refill lapses of 278%, and an 18% decrease in overall PrEP users [70[■]]. In South Africa, a PrEP programme for pregnant woman reported greater than two-fold higher odds of a missed visit, in spite of no reported change in sexual activity by patients [71]. Although one study in Australia showed that most people stopping PrEP reported a decrease in sexual behaviour as the motivator, others reported concerns about contracting COVID-19 and difficulty making appointments as the reason for their PrEP discontinuation [69]. One strategy patients on PrEP have used due to lower sexual activity and/or decreased medication access during COVID-19 is to transition to 2-1-1/on-demand PrEP [69,72].

In other settings, COVID-19 has led to greater stigma, economic vulnerability, loss of housing and continued or increased exposure to HIV for vulnerable populations [73–75,67[■]], with greater stringency of lockdowns associated with less access to PrEP, condoms and HIV testing [76[■],77]. San Francisco has reported approximately a 40% decrease in HIV testing citywide, a 90% decrease in community-based HIV testing and a 70% decrease in testing for sexually transmitted infections (STIs) [78]. Alarmingly, a large sexual health clinic in Boston has reported an 85% decrease in overall HIV testing [70[■]]. In many settings, contact tracers have been redeployed to the COVID-19 epidemic [79], which could potentially impact the ability of public health agencies to respond to HIV outbreaks.

In terms of the impact of the COVID-19 pandemic on HIV treatment, disruption in care services, lower access to antiretrovirals and deepening of socioeconomic vulnerabilities – including a loss of social support, increased food insecurity, and loss of stable housing – will all affect treatment access. In Wuhan, China, at the height of their COVID-19 epidemic, many healthcare facilities were converted into hospitals that only treated COVID-19 patients, leading to interruptions in non-COVID-19 care delivery, such as for HIV [80]. The city lockdown and cessation of public transportation also resulted in a lack of medication access for those with chronic diseases [81,82]. Per a UNAIDS survey, one-third of PLWH in China on February 19, 2020, expressed concern that they would run out of ART in a few days, and half said they did not know where to procure their next ART refill [81,82]. A large survey of over 10 000 men who have sex with men across 20 countries, which included over 1000 PLWH, reported that approximately one-fifth of PLWH had not been able to access their provider, with only 14% reporting access to telemedicine, and nearly 50% had not been able to refill their HIV medicine remotely [76[■],77].

Even with access to telemedicine, the loss of the social services and in-person support available in HIV clinics for vulnerable patients will impact the health of PLWH. After shelter in place ordinances were mandated in San Francisco [61], a large HIV clinic serving publicly insured patients reported a 31% increase in the odds of unsuppressed viral loads, in spite of stable retention in care recorded via telemedicine, with homeless PLWH disproportionately impacted [83[■]]. Although telemedicine may increase access to care services in the context of decreased access to in-person visits, it may not be sufficient to stem the deleterious effects of the pandemic [75,83[■]]. The digital divide [84] decreased access to social services, and increasing socioeconomic and housing insecurity may disproportionately impact those with the greatest need, such as homeless PLWH, leading to worsening viral suppression, health outcomes and potentially mortality [75,83[■],85]. Interruption of antiretroviral access, even if brief, could increase death up to 10% among PLWH in low and middle-income countries according to a modelling study [86]. In another modelling study by UNAIDS, a 6-month interruption in antiretroviral access across 50% of the population living with HIV could lead to nearly 300 000 excess deaths in sub-Saharan Africa next year [87].

Impact on social determinants of health for people living with HIV

PLWH are particularly vulnerable to disruptions in healthcare due to increased rates of mental illness [88], marginal housing [89], food insecurity [90], substance use [91] and other chronic diseases (e.g. diabetes mellitus, CVD) comanaged in the same clinic [92]. During the Ebola epidemic in West Africa, food insecurity, substance use and poverty disproportionately impacted Ebola outcomes, but the impacts were magnified among PLWH [93,63,62]. PLWH who experience food insecurity often depend on clinic-run programmes for social services, including access to food. PLWH with food insecurity already have higher rates of virologic failure and death, [94,95] with food insecurity during and after the COVID-19 pandemic for PLWH expected to dramatically increase [96].

Homeless PLWH also have substantially lower rates of HIV viral suppression and higher mortality than housed PLWH [97,85], and efforts to increase clinic-based ART access and support among homeless PLWH, [98] could be undermined by decreased funding and access to in-clinic services during and after the COVID-19 pandemic. As the COVID-19 pandemic is associated with increased stress, anxiety, boredom and social isolation, there is concern that substance and alcohol consumption could

increase as a coping mechanism [99–104,105^{***}]. Those with histories of alcohol and substance use disorders are at a high risk of relapse under stressful situations [106]. The vast majority of PLWH in the U.S. have high rates of current or past substance use [107], and therefore could experience relapse or increased substance use, threatening HIV care outcomes [108,109]. Finally, PLWH, especially older PLWH, experience high rates of social isolation [91,110,111] – even prior to the COVID-19 pandemic – a situation that will worsen with physical distancing mandates [105^{***}].

LESSONS FROM THE HIV PANDEMIC FOR THE COVID-19 PANDEMIC

Racial and ethnic disparities

Racial and ethnic disparities in COVID-19 incidence and outcomes have been described across multiple settings [112–120], with racial and ethnic minority groups similarly disproportionately represented among HIV/COVID-19-coinfected patients. In France, PLWH with more severe COVID-19 disease were more likely to be from sub-Saharan Africa [121]. In London, HIV/COVID-19-coinfected patients were more likely to be black than the general population of PLWH [122]. In Boston, in a case series of PLWH admitted to the hospital with COVID-19 infection, almost 80% were black or Latinx compared with 40% of the catchment clinic population [45^{*}]. Multiple case series of PLWH hospitalized with COVID-19 in other metropolitan areas in the USA describe high proportions of black patients: 85% of 20 PLWH hospitalized for COVID-19 across three hospitals in Atlanta were black [34^{***}], and 93% of patients in a case series of 27 PLWH hospitalized in New Jersey were black [31], although the demographics of the source populations were not described.

Racial/ethnic disparities in COVID-19 disease appear to be influenced by the social determinants of health: crowded housing, employment in essential work, decreased healthcare access, greater comorbidity burden all likely contribute to greater disease burden among black and Latinx PLWH [112–119]. Interventions will likely be needed to support the ability of people at-risk of COVID-19 to physically distance, such as food, housing and economic assistance, or racial/ethnic disparities may worsen. As the HIV epidemic has also had a disproportionate impact on racial and ethnic minorities, both in terms of HIV risk and poorer prevention and treatment outcomes, lessons from the HIV pandemic and support programmes for PLWH should be translated for those at risk of COVID-19.

The HIV epidemic has informed scientific, regulatory and public health responses to SARS-CoV-2

Regulatory and approval process

Finally, the lessons of the HIV epidemic have informed clinical responses to COVID-19 through their influence on disseminating paradigms for disease testing, contact tracing, clinical trial frameworks and the infrastructure for therapeutics and vaccine testing, and the influence at the FDA level on more rapid review and approval of potential testing platforms and treatments. Moreover, the lessons from the HIV field to COVID-19 extend to involving the community in testing and treatment campaigns, with community-based participatory research facilitating effective COVID-19 mitigation strategies.

Early in the pandemic, HIV protease inhibitors were tested out of hope that similarities between the coronavirus protease and the HIV protease could be leveraged, although trials to date have been disappointing [123]. Investments in HIV research over the last 4 decades have built capacity and infrastructure for immunology, vaccinology and therapeutics research that has since been repurposed for the fight against COVID-19 [124]. For instance, worldwide recruitment processes, testing sites and clinical trials networks such as the AIDS Clinical Trials Group (ACTG) are leading COVID-19 therapeutic trials; the HIV Vaccines Trial Network (HVTN) and the HIV Prevention Trials Network (HPTN) have contributed to the COVID-19 Prevention Trials Network, which is performing clinical trials for COVID-19 vaccines and mAbs, characterizing immune responses to COVID-19 (HVTN 405/HPTN 1901), and has developed a COVID-19 specimen bank [125].

The response to the HIV epidemic has helped facilitate a more rapid review and approval of COVID-19 drugs and has also facilitated a greater involvement of patients, clinicians and advocates in the drug-development process. HIV advocacy organizations, such as Project Inform and The AIDS Coalition to Unleash Power (ACT-UP) advocated for faster reviews and approvals for severely debilitating or life-threatening diseases without effective treatments, most notably through the 1988 demonstration at the Federal Drug Administration (FDA) Parklawn headquarters [126,127]. The FDA instituted rapid review and accelerated approval for life-threatening diseases with few available treatments in direct response to these efforts of HIV activists [126–128]. The parallel track, that was instituted in 1992, allowed PLWH who were not eligible for clinical trials to gain access to HIV

medications while efficacy trials were still ongoing [129,130]. To date, the availability of potential COVID-19 therapies such as remdesivir and convalescent plasma for those not eligible for clinical trials has been influenced by these changes in FDA policy [130].

However, debates about the balance between demonstration of the efficacy and safety of treatments and the rights of patients to access potential treatments, highlighted prominently during the HIV epidemic, have already come to a head in response to review of potential COVID-19 therapies and vaccines under emergency use authorizations (EUs) [130]. EUs allow use of unapproved medical products to treat serious or life-threatening conditions in response to a declared public health emergency when alternatives do not exist [131]. U.S. HIV and Infectious Diseases specialists and professional societies have called for full licensure of a COVID-19 vaccine with independent scrutiny of vaccine data, rather than under an EUA, with the goal of combating public distrust and concerns about safety of a COVID-19 vaccine [132].

Public health responses

The response to the HIV epidemic has also profoundly influenced public health strategies implemented to combat the COVID-19 epidemic. Contact tracing programmes previously developed, at least in part, to battle the HIV epidemic have been expanded and repurposed to address the COVID-19 epidemic [133–135]. The need to provide testing within communities most at risk, at low-cost or no-cost with minimal barriers, was highlighted early in the HIV epidemic [134]. Efforts to combat stigma and avoid ‘quarantine shaming’, and the negative impacts of policies that stigmatize those with infectious diseases, are important lessons that public health experts are using to craft COVID-19 policies derived from experience fighting the HIV epidemic [133,136]. For instance, the ‘COVID-19 prevention toolbox,’ modelled off of HIV prevention efforts, focuses on both the individual and socioecological factors that lead to disease risk and disease outcomes [133,134]. COVID-19 prevention strategies influenced by this paradigm include: acknowledgement that physical distancing is not feasible for many vulnerable populations, the need for harm reduction interventions such as masking and expanded access to testing within communities most at risk, resources to combat food insecurity and lost income, and availability of quarantine hotels to combat the inability to social distance in a shelter, within crowded housing, or on the street [27,133,137].

CONCLUSION

This review synthesizes the current level of evidence on how HIV influences COVID-19 susceptibility and outcomes and how the COVID-19 epidemic is disrupting HIV care. PLWH do not seem to have a markedly elevated risk for COVID-19 infection, although well designed prospective cohorts are still needed. In sub-Saharan Africa, HIV may be a significant risk factor for severe outcomes with COVID-19, but ongoing study is needed. Conversely, the COVID-19 pandemic is threatening worldwide gains in UNAIDS 90 : 90:90 and U.S. Ending the HIV Epidemic targets by disrupting health systems, economies, and the health of PLWH. HIV has informed the public health response to COVID-19 and many lessons, including how to improve the disproportionate impact of infectious diseases among vulnerable populations, continue to be translated. The ongoing collision of these two global pandemics will continue to need study and interventions to mitigate the effects of COVID-19 on HIV efforts worldwide.

Acknowledgements

None.

Financial support and sponsorship

This work was funded by National Institutes of Health/ National Institute of Allergy and Infectious Diseases R01AI158013.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Fauci AS, Lane HC, Redfield RR. Covid-19: navigating the uncharted. *N Engl J Med* 2020; 382:1268–1269.
2. Leno NN, Delamou A, Koita Y, *et al.* Ebola virus disease outbreak in Guinea: what effects on prevention of mother-to-child transmission of HIV services? *Reprod Health* 2018; 15:60.
3. Blanco JL, Ambrosioni J, Garcia F, *et al.* COVID-19 in patients with HIV: clinical case series. *Lancet HIV* 2020; 7:e314–e316.
4. Shannon FQ 2nd, Horace-Kwemi E, Najjema B, *et al.* Effects of the 2014 Ebola outbreak on antenatal care and delivery outcomes in Liberia: a nationwide analysis. *Public Health Action* 2017; 7(Suppl 1):S88–S93.
5. Wu C, Chen X, Cai Y, *et al.* Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020; 180:934–943.
6. Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395:1054–1062.
7. Guan W-J, Ni Z-Y, Hu Y, *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; 382:1708–1720.
8. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020; 323:1239–1242.

9. Liang W, Guan W, Chen R, *et al.* Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020; 21:335–337.
10. Jacobs GP, Bhat P, Owiti P, *et al.* Did the 2014 Ebola outbreak in Liberia affect HIV testing, linkage to care and ART initiation? *Public Health Action* 2017; 7(Suppl 1):S70–S75.
11. Triant VA. Cardiovascular disease and HIV infection. *Curr HIV/AIDS Rep* 2013; 10:199–206.
12. Fitzpatrick ME, Kunisaki KM, Morris A. Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy. *AIDS* 2018; 32:277–292.
13. Crothers K. Chronic obstructive pulmonary disease in patients who have HIV infection. *Clin Chest Med* 2007; 28:575–587vi.
14. Inciarte A, Gonzalez-Cordon A, Rojas J, *et al.* Clinical characteristics, risk factors, and incidence of symptomatic COVID-19 in adults living with HIV: a single-center, prospective observational study. *AIDS* 2020.
- This is one of the largest population-based studies in Europe examining the impact of HIV status on incidence of COVID-19 infection. They did not find increased COVID-19 incidence or severity among PLWH, with no difference by ART class.
15. Del Amo J, Polo R, Moreno S, *et al.* Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. *Ann Intern Med* 2020.
- This is one of the largest cohort studies in Europe examining disease severity and incidence of COVID-19 among PLWH. Similarly, they did not find a disproportionate impact of COVID-19 among PLWH.
16. Charre C, Icard V, Pradat P, *et al.* COVID-19 attack rate in HIV-infected patients and in PrEP users. *AIDS* 2020.
17. Huang J, Xie N, Hu X, *et al.* Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City: a population-based cohort study. *Clin Infect Dis* 2020.
- One of the few population-based studies of the impact of HIV status on COVID-19 presentations in Asia.
18. Park LR, Sigel K, Rodriguez-Barradas M, editor. COVID-19 in the Largest US HIV Cohort. *AIDS* 2020: 23rd International AIDS Conference Virtual; 6–10 July 2020.
- Although presented only as a poster, this study leverages the Veteran's Aging Cohort Study to examine COVID-19 presentations among PLWH across the USA. The study found higher testing rates but not higher incidence of COVID-19 among PLWH.
19. Sachdev DME, Hsu L, Scheer S, *et al.* COVID-19 susceptibility and outcomes among people living with HIV in San Francisco. *J Acquir Immune Defic Syndr*. doi: 10.1097/QAI.0000000000002531. (in press).
- This is a large population-based study in San Francisco, which leverages mandatory reporting of COVID-19 results to examine incidence and severity of COVID-19 by HIV status. The study found increased test positivity among PLWH, but not increased severity.
20. Mdofo R, Frazier EL, Dube SR, *et al.* Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. *Ann Intern Med* 2015; 162:335–344.
21. Shiao S, Arpadi SM, Yin MT, Martins SS. Patterns of drug use and HIV infection among adults in a nationally representative sample. *Addict Behav* 2017; 68:39–44.
22. Williams EC, Hahn JA, Saitz R, *et al.* Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. *Alcohol Clin Exp Res* 2016; 40:2056–2072.
23. Testino G. Are patients with alcohol use disorders at increased risk for Covid-19 infection? *Alcohol Alcohol* 2020; 55:344–346.
24. Fazel S, Geddes JR, Kushel M. The health of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations. *Lancet* 2014; 384:1529–1540.
25. Aidala AA, Lee G, Abramson DM, *et al.* Housing need, housing assistance, and connection to HIV medical care. *AIDS Behav* 2007; 11(Suppl 6):101–115.
26. Mosites E, Parker EM, Clarke KEN, *et al.* Assessment of SARS-CoV-2 infection prevalence in homeless shelters: four U.S. cities, March 27–April 15, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:521–522.
- An important study that demonstrated the risks of outbreaks in congregate settings such as homeless shelters in four U.S. cities, highlighting the potentially disproportionate impact of COVID-19 among populations with greater rates of unstable housing, such as PLWH.
27. Imbert E, Kinley PM, Scarborough A, *et al.* Coronavirus disease 2019 (COVID-19) outbreak in a San Francisco homeless shelter. *Clin Infect Dis* 2020.
28. Gervasoni C, Meraviglia P, Riva A, *et al.* Clinical features and outcomes of HIV patients with coronavirus disease. *Clin Infect Dis* 2020.
29. Byrd KM, Beckwith CG, Garland JM, *et al.* SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. *J Int AIDS Soc* 2020; 23:e25573.
30. Calza L, Bon I, Tadolini M, *et al.* COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy. *Infection* 2020.
31. Okoh AK, Bishburg E, Grinberg S, Nagarakanti S. COVID-19 pneumonia in patients with HIV: a case series. *J Acquir Immune Defic Syndr* 2020.
32. Shalev N, Scherer M, LaSota ED, *et al.* Clinical characteristics and outcomes in people living with HIV hospitalized for COVID-19. *Clin Infect Dis* 2020.
33. Sigel K, Swartz T, Golden E, *et al.* Covid-19 and people with HIV infection: outcomes for hospitalized patients in New York City. *Clin Infect Dis* 2020.
34. Collins LF, Moran CA, Oliver NT, *et al.* Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease 2019 in Atlanta, GA. *AIDS* 2020.
- A multisite study in Atlanta demonstrating the disproportionate impact of COVID-19 among Black PLWH.
35. Ridgway JP, Farley B, Benoit JL, *et al.* A case series of five people living with HIV hospitalized with COVID-19 in Chicago, Illinois. *AIDS Patient Care STDS* 2020; 34:331–335.
36. Dandachi D, Geiger G, Montgomery MW, *et al.* Characteristics, comorbidities, and outcomes in a multicenter registry of patients with HIV and coronavirus disease-19. *Clin Infect Dis* 2020.
37. Karmen-Tuohy S, Carlucci PM, Zervou FN, *et al.* Outcomes among HIV-positive patients hospitalized with COVID-19. *J Acquir Immune Defic Syndr* 2020; 85:6–10.
38. Guo W, Ming F, Feng Y, *et al.* Patterns of HIV and SARS-CoV-2 co-infection in Wuhan, China. *J Int AIDS Soc* 2020; 23:e25568.
39. Boule A, Davies MA, Hussey H, *et al.* Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. *Clin Infect Dis* 2020.
- The largest population-based study published to date of the impact of HIV status on COVID-19 mortality, demonstrating a higher risk of death from COVID-19 among PLWH. The cohort contained a high number of PLWH who were not virologically suppressed or were living with uncontrolled diabetes, potentially explaining the divergent results compared with Europe and the US.
40. Ssentongo P, Ssentongo AE, Heilbrunn ES, *et al.* Association of cardiovascular disease and 10 other preexisting comorbidities with COVID-19 mortality: a systematic review and meta-analysis. *PLoS One* 2020; 15:e0238215.
41. Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. *J Am Soc Hypertens* 2017; 11:530–540.
42. Helleberg M, May MT, Ingle SM, *et al.* Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. *AIDS* 2015; 29:221–229.
43. Murphy JD, Liu B, Parascandola M. Smoking and HIV in sub-Saharan Africa: a 25-country analysis of the demographic health surveys. *Nicotine Tob Res* 2019; 21:1093–1102.
44. Gudipati S, Brar I, Murray S, *et al.* Descriptive analysis of patients living with HIV affected by COVID-19. *J Acquir Immune Defic Syndr* 2020; 85:123–126.
45. Meyerowitz EA, Kim AY, Ard KL, *et al.* Disproportionate burden of COVID-19 among racial minorities and those in congregate settings among a large cohort of people with HIV. *AIDS* 2020.
- An analysis demonstrating the disproportionate impact of COVID-19 among black and Latinx PLWH in Boston.
46. Saag M. Special section: COVID-19 among people living with HIV. *AIDS* 2020; 34:1755–1756.
47. Wu CY, Jan JT, Ma SH, *et al.* Small molecules targeting severe acute respiratory syndrome human coronavirus. *Proc Natl Acad Sci U S A* 2004; 101:10012–10017.
48. de Wilde AH, Jochmans D, Posthuma CC, *et al.* Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. *Antimicrob Agents Chemother* 2014; 58:4875–4884.
49. Chan JF-W, Yao Y, Yeung M-L, *et al.* Treatment with lopinavir/ritonavir or interferon- β 1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. *J Infect Dis* 2015; 212:1904–1913.
50. Fintelman-Rodrigues N, Sacramento CQ, Ribeiro Lima C, *et al.* Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production. *Antimicrob Agents Chemother* 2020; 64:.
51. Cao B, Wang Y, Wen D, *et al.* A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med* 2020; 382:1787–1799.
- An important randomized controlled trial completed in the early COVID-19 epidemic, which did not find an impact of lopinavir-ritonavir on COVID-19 disease severity.
52. Group RC. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2020.
- A large randomized controlled trial completed by the RECOVERY investigators, which did similarly not find an impact of lopinavir-ritonavir on COVID-19 disease severity.
53. Schoergenhofer C, Jilma B, Stimpff T, *et al.* Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19). *Ann Intern Med* 2020; 173:670–672.
54. Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. *Life Sci* 2020; 253:117592.
55. National Institutes of Health. COVID-19 treatment guidelines. [Accessed October 19 Aahwctng].
56. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents Living with HIV. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/what-start-initial-combination-regimens-antiretroviral-naive?view=full>. [Accessed 10 September 2020].

57. Azambuja MI. Spanish flu and early 20th-century expansion of a coronary heart disease-prone subpopulation. *Tex Heart Inst J* 2004; 31:14–21.

58. Myrskylä M, Mehta NK, Chang VW. Early life exposure to the 1918 influenza pandemic and old-age mortality by cause of death. *Am J Public Health* 2013; 103:e83–e90.

59. Helgertz J, Bengtsson T. The long-lasting influenza: the impact of fetal stress during the 1918 influenza pandemic on socioeconomic attainment and health in Sweden. *Demography* 2019; 56:1389–1425.

60. Nickol ME, Kindrachuk J. A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918–1919. *BMC Infect Dis* 2019; 19:117.

61. Gamanga AH, Owiti P, Bhat P, *et al*. The Ebola outbreak: effects on HIV reporting, testing and care in Bonthe district, rural Sierra Leone. *Public Health Action* 2017; 7(Suppl 1):S10–S15.

62. Nagel E, Blackowicz MJ, Sahr F, Jarrett OD. Impact of the Ebola epidemic on clinical outcomes of HIV-infected soldiers and their dependents in Sierra Leone. *Int J STD AIDS* 2019; 30:106–112.

63. Kelly JD, Richardson ET, Drasher M, *et al*. Food insecurity as a risk factor for outcomes related to Ebola virus disease in Kono district, Sierra Leone: a cross-sectional study. *Am J Trop Med Hyg* 2018; 98:1484–1488.

64. Fauci AS, Redfield RR, Sigounas G, *et al*. Ending the HIV epidemic: a plan for the United States. *JAMA* 2019; 321:844–845.

65. Allday E. Eradicate AIDS? Coronavirus stands in the way. *San Francisco Chronicle* <https://www.sfchronicle.com/bayarea/article/Eradicate-AIDS-Coronavirus-stands-in-the-way-15389943php>. [Accessed 10 July 2020].

66. Santos GM, Ackerman B, Rao A, *et al*. Economic, mental health, HIV prevention and HIV treatment impacts of COVID-19 and the COVID-19 response on a global sample of cisgender gay men and other men who have sex with men. *AIDS Behav* 2020.

67. Lamontagne E. COVID-19 pandemic increases socioeconomic vulnerability of LGBT+ communities and their susceptibility to HIV. *AIDS* 2020.

A large multicountry survey-based analysis completed on social media examining the impact of the COVID-19 on the health of PLWH and those at-risk of HIV.

68. Mehrotra A, Chernew M, Linetsky D, *et al*. The impact of the COVID-19 pandemic on outpatient visits: a rebound emerges. *The Commonwealth Fund*. 2020. <https://www.commonwealthfund.org/publications/2020/apr/impact-covid-19-outpatient-visits>. [Accessed 10 June 2020]

69. Chow EPF, Hocking JS, Ong JJ, *et al*. Changing the use of HIV preexposure prophylaxis among men who have sex with men during the COVID-19 pandemic in Melbourne, Australia. *Open Forum Infect Dis* 2020; 7:ofaa275.

70. Krakower D. Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center. *AIDS* 2020 San Francisco and Oakland CA 2020; 10 July 2020 [Abstract# OACLB01]

An analysis showing the impact of COVID-19 on PrEP refills and HIV testing in a large sexual health clinic in Boston.

71. Davey DLJ, Bekker LG, Mashele N, *et al*. PrEP retention and prescriptions for pregnant women during COVID-19 lockdown in South Africa. *Lancet HIV* 2020.

72. Molina JM, Charreau I, Spire B, *et al*. Efficacy, safety, and effect on sexual behaviour of on-demand preexposure prophylaxis for HIV in men who have sex with men: an observational cohort study. *Lancet HIV* 2017; 4:e402–e410.

73. Torres TS, Hoagland B, Bezerra DRB, *et al*. Impact of COVID-19 pandemic on sexual minority populations in Brazil: an analysis of social/racial disparities in maintaining social distancing and a description of sexual behavior. *AIDS Behav* 2020.

74. Stephenson R, Chavanduka TMD, Rosso MT, *et al*. Sex in the time of COVID-19: results of an online survey of gay, bisexual and other men who have sex with men's experience of sex and HIV prevention during the US COVID-19 epidemic. *AIDS Behav* 2020.

75. Riley ED, Hickey MD, Imbert E, *et al*. COVID-19 and HIV spotlight the U.S. imperative for permanent affordable housing. *Clin Infect Dis* 2020.

76. Rao A, Rucinski K, Jarrett B, *et al*. Global interruptions in HIV prevention and treatment services as a result of the response to COVID-19: results from a social media-based sample of men who have sex with men. *AIDS* 2020 San Francisco/Oakland 2020; 14 July 2020 [Abstract OALB0104]

A large multicountry survey analysis on social media examining the impact of COVID-19 on HIV treatment and prevention access among MSM.

77. Rao A, Rucinski K, Jarrett B, *et al*. Potential interruptions in HIV prevention and treatment services for gay, bisexual, and other men who have sex with men associated with COVID-19. *medRxiv* 2020.

78. Getting to Zero San Francisco. Impact of the COVID-19 epidemic on San Francisco's HIV Community and Getting to Zero July 2020. <https://www.gettingtozerosf.org/wp-content/uploads/2020/07/July-2020-Impact-of-COVID19-epidemic-on-San-Francisco%E2%80%99s-HIV-Community-and-Getting-to-Zero.pdf>. 2020. [Accessed 1 September 2020]

79. Centers for Disease Control and Prevention. Operational considerations for adapting a contact tracing program to respond to the COVID-19 pandemic. 2020. <https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/operational-considerations-contact-tracing.html>. [Accessed 1 September 2020]

80. 'No Way Out': In China, coronavirus takes toll on other patients. *New York Times*. 3 March 2020. <https://www.nytimes.com/2020/03/03/world/asia/china-coronavirus-cancer.html>.

81. UNAIDS and China working together during the COVID-19 outbreak to ensure that people living with HIV continue to get treatment. 19 February 2020. https://www.unaids.org/en/resources/presscentre/pressreleaseand-statementarchive/2020/february/20200218_china_covid19.

82. China HIV patients risk running out of AIDS drugs in days: UNAIDS. 19 February 2020. <https://www.reuters.com/article/us-china-health-aids/china-hiv-patients-risk-running-out-of-aids-drugs-in-days-unaids-idUSKBN20D1RE>.

83. Spinelli MA, Hickey MD, Glidden DV, *et al*. Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19 AIDS 2020. An analysis showing worsening viral suppression, particularly among homeless PLWH, in the context of the COVID-19 epidemic.

84. Philbin MM, Parish C, Pereyra M, *et al*. Health disparities and the digital divide: the relationship between communication inequalities and quality of life among women in a nationwide prospective cohort study in the United States. *J Health Commun* 2019; 24:405–412.

85. Spinelli MA, Hessol NA, Schwarcz S, *et al*. Homelessness at diagnosis is associated with death among people with HIV in a population-based study of a US city. *AIDS* 2019; 33:1789–1794.

86. Hogan AB, Jewell BL, Sherrard-Smith E, *et al*. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. *Lancet Glob Health* 2020; 8:e1132–e1141.

87. Jewell BL, Mudimu E, Stover J, *et al*. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. *Lancet HIV* 2020; 7:e629–e640.

88. Gostin LO. A tale of two diseases: mental illness and HIV/AIDS. *Milbank Q* 2015; 93:687–690.

89. Stanic A, Rybin D, Cannata F, *et al*. The impact of the housing status on clinical outcomes and healthcare utilization among individuals living with HIV. *AIDS Care* 2019; 1–9.

90. The Lancet H. The syndemic threat of food insecurity and HIV. *Lancet HIV* 2020; 7:e75.

91. Bosisis CM, St Louis J. HIV and substance use disorder: role of the HIV physician. *Infect Dis Clin North Am* 2019; 33:835–855.

92. Marcus JL, Leyden WA, Alexeff SE, *et al*. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection. *JAMA Netw Open* 2020; 3:e207954.

93. Elston JW, Cartwright C, Ndumbi P, Wright J. The health impact of the 2014–15 Ebola outbreak. *Public Health* 2017; 143:60–70.

94. Weiser SD, Fernandes KA, Brandon EK, *et al*. The association between food insecurity and mortality among HIV-infected individuals on HAART. *J Acquir Immune Defic Syndr* 2009; 52:342–349.

95. Weiser SD, Yuan C, Guzman D, *et al*. Food insecurity and HIV clinical outcomes in a longitudinal study of urban homeless and marginally housed HIV-infected individuals. *AIDS* 2013; 27:2953–2958.

96. McLinden T, Stover S, Hogg RS. HIV and food insecurity: a syndemic amid the COVID-19 pandemic. *AIDS Behav* 2020; 24:2766–2769.

97. Clemezi-Allen A, Geng E, Christopoulos K, *et al*. Degree of housing instability shows independent 'Dose-Response' with virologic suppression rates among people living with human immunodeficiency virus. *Open Forum Infect Dis* 2018; 5:ofy035.

98. Dombrowski JC, Galagan SR, Ramchandani M, *et al*. HIV care for patients with complex needs: a controlled evaluation of a walk-in, incentivized care model. *Open Forum Infect Dis* 2019; 6:ofz294.

99. Ahmed MZ, Ahmed O, Aibao Z, *et al*. Epidemic of COVID-19 in China and associated psychological problems. *Asian J Psychiatry* 2020; 51:102092.

100. Clay JM, Parker MO. Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? *Lancet Public Health* 2020; 5:e259.

101. Rehm J, Kilian C, Ferreira-Borges C, *et al*. Alcohol use in times of the COVID 19: implications for monitoring and policy. *Drug Alcohol Rev* 2020; 39:301–304.

102. Da BL, Im GY, Schiano TD. COVID-19 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease. *Hepatology* 2020.

103. Lee SA. Coronavirus Anxiety Scale: a brief mental health screener for COVID-19 related anxiety. *Death Stud* 2020; 44:393–401.

104. Volkow ND. Collision of the COVID-19 and addiction epidemics. *Ann Intern Med* 2020; 173:61–62.

105. Rozanova J, Sheno S, Zaviryukha I, *et al*. Social support is key to retention in care during Covid-19 pandemic among older people with HIV and substance use disorders in Ukraine. *Subst Use Misuse* 2020; 55:1902–1904.

An analysis in Ukraine examining the impact of COVID-19 on PLWH who use substances. This study and others highlight concerns that the HIV epidemic could worsen among people who use drugs during COVID-19.

106. Sinha R. How does stress lead to risk of alcohol relapse? *Alcohol Res Curr Rev* 2012; 34:432–440.

107. Crane HM, McCaul ME, Chander G, *et al*. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. *AIDS Behav* 2017; 21:1914–1925.

108. Williams EC, McGinnis KA, Bobb JF, *et al*. Changes in alcohol use associated with changes in HIV disease severity over time: a national longitudinal study in the Veterans Aging Cohort. *Drug Alcohol Depend* 2018; 189:21–29.

109. Williams EC, McGinnis KA, Tate JP, *et al.* HIV disease severity is sensitive to temporal changes in alcohol use: a national study of VA patients with HIV. *J Acquir Immune Defic Syndr* 2019; 81:448–455.
110. Mazonson P, Berko J, Loo T, *et al.* Loneliness among older adults living with HIV: the 'older old' may be less lonely than the 'younger old'. *AIDS Care* 2020; 1–8.
111. Greene M, Hessel NA, Perissinotto C, *et al.* Loneliness in older adults living with HIV. *AIDS Behav* 2018; 22:1475–1484.
112. Hsu HE, Ashe EM, Silverstein M, *et al.* Race/ethnicity, underlying medical conditions, homelessness, and hospitalization status of adult patients with COVID-19 at an Urban Safety-Net Medical Center: Boston, Massachusetts. *MMWR Morb Mortal Wkly Rep* 2020; 69:864–869.
113. Karaca-Mandic P, Georgiou A, Sen S. Assessment of COVID-19 hospitalizations by race/ethnicity in 12 states. *JAMA Intern Med* 2020.
114. McCarty TR, Hathorn KE, Redd WD, *et al.* How do presenting symptoms and outcomes differ by race/ethnicity among hospitalized patients with COVID-19 infection? Experience in Massachusetts. *Clin Infect Dis* 2020.
115. Millett GA, Jones AT, Benkeser D, *et al.* Assessing differential impacts of COVID-19 on black communities. *Ann Epidemiol* 2020; 47:37–44.
116. Moore JT, Ricaldi JN, Rose CE, *et al.* Disparities in incidence of COVID-19 among underrepresented racial/ethnic groups in counties identified as hot-spots during June 5-18, 2020-22 States, February-June 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:1122–1126.
117. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. *N Engl J Med* 2020; 382:2534–2543.
118. Raifman MA, Raifman JR. Disparities in the population at risk of severe illness from COVID-19 by race/ethnicity and income. *Am J Prev Med* 2020; 59:137–139.
119. Rentsch CT, Kidwai-Khan F, Tate JP, *et al.* Covid-19 by race and ethnicity: a national cohort study of 6 million United States veterans. *medRxiv* 2020.
120. Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. *JAMA* 2020; 323:2466–2467.
121. Etienne N, Karmochkine M, Slama L, *et al.* HIV infection and COVID-19: risk factors for severe disease. *AIDS* 2020.
122. Childs K, Post FA, Norcross C, *et al.* Hospitalized patients with COVID-19 and HIV: a case series. *Clin Infect Dis* 2020.
123. Cao B, Wang Y, Wen D, *et al.* A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *N Engl J Med* 2020; 382:1787–1799.
124. Johnson C, Bernstein L. Decades of research on an HIV vaccine boost the bid for one against coronavirus. *Washington Post*. 14 July 2020. https://www.washingtonpost.com/health/decades-of-research-on-an-hiv-vaccine-boosts-the-bid-for-one-against-coronavirus/2020/07/13/3eb1a37a-c216-11ea-b4f6-cb39cd8940fb_story.html. [Accessed 1 September 2020]
125. NIH. NIH launches clinical trials network to test COVID-19 vaccines and other prevention tools. 8 July 2020. <https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trials-network-test-covid-19-vaccines-other-prevention-tools>. [Accessed 1 September 2020].
126. Grossman LA. AIDS activists, FDA regulation, and the amendment of America's Drug Constitution. *Am J Law Med* 2016; 42:687–742.
127. Expanded and early access and patient assistance programs for other experimental drugs from their manufacturers. *Critical Path AIDS Project* 1998; 43–64.
128. Cohen C, Shevitz A, Mayer K. Expanding access to investigational new therapies. *Prim Care* 1992; 19:87–96.
129. Expanded availability of investigational new drugs through a parallel track mechanism for people with AIDS, and other HIV-related, disease—PHS. Notice final policy, statement, Fed, Regist 1992; 57:13250–13259.
130. George M. The fight against AIDS has shaped how potential covid-19 drugs will reach patients. *Washington Post* 2020; 29 April [Accessed 1 September 2020]. <https://www.washingtonpost.com/outlook/2020/04/29/fight-against-aids-has-shaped-how-potential-covid-19-drugs-will-reach-patients/>.
131. Krause PR, Gruber MF. Emergency use authorization of covid vaccines: safety and efficacy follow-up considerations. *N Engl J Med* 2020.
132. Infectious Disease Society of America and HIV Medicine Association. Don't cut corners in COVID-19 vaccine approval. <https://www.idsociety.org/news-publications-new/articles/2020/infectious-diseases-specialists-to-fda-dont-cut-corners-in-covid-19-vaccine-approval/>. [Accessed 20 October 2020]
133. Eaton LA, Kalichman SC. Social and behavioral health responses to COVID-19: lessons learned from four decades of an HIV pandemic. *J Behav Med* 2020; 43:341–345.
134. Hargreaves J, Davey C; Group for lessons from pandemic HIVpftC-r. Three lessons for the COVID-19 response from pandemic HIV. *Lancet HIV* 2020; 7:e309–e311.
135. Nosyk B, Armstrong WS, Del Rio C. Contact tracing for COVID-19: an opportunity to reduce health disparities and End the HIV/AIDS Epidemic in the US. *Clin Infect Dis* 2020.
136. Marcus J. Quarantine fatigue is real. *The Atlantic*. 2020. May 11. Accessed September 2, 2020. <https://www.theatlantic.com/ideas/archive/2020/05/quarantine-fatigue-real-and-shaming-people-wont-help/611482/>.
137. KVTU-Fox. SF supervisor launches program to provide wages for COVID-19 positive workers. 2 July 2020. <https://www.ktvu.com/news/sf-supervisor-launches-program-to-provide-wages-for-covid-19-positive-workers>. [Accessed 30 October 2020]